The Risk of Musculoskeletal Adverse Events With Fluoroquinolones in Children

Abstract

Get full access to this article

View all access options for this article.

References

Linseman

Hamptom

Branstetter

. Quinolone-induced arthropathy in the neonatal mouse: morphological analysis of articular lesions produced by pipemidic acid and ciprofloxacin. Fundam Appl Toxicol. 1995;28:59-64.

Kato

Onodera

. Morphological investigation of cavity formation in articular cartilage induced by ofloxacin in rats. Fundam Appl Toxicol. 1988;11:110-119.

Gough

Barsoum

Mitchell

McGuire

Iglesia

. Juvenile canine drug-induced arthropathy: clinicopathological studies on articular lesions caused by oxolinic and pipemidic acids. Toxicol Appl Pharmacol. 1979;51:177-187.

Machida

Kusajima

Aijima

Maeda

Ishida

Uchida

. Toxicokinetic study of norfloxacin-induced arthroplasty in juvenile animals. Toxicol Appl Pharmacol. 1990;105:403-412.

Bendele

Hulman

Harvey

Hrubey

Chandrasekha

. Passive role of articular chondrocytes in quinolone-induced arthropathy in guinea pigs. Toxicol Pathol. 1990;18:304-312.

Ewing

Ness

. Quinolone arthropathy in juvenile ferrets. Vet Pathol. 1995;32:599.

von Keutz

Ruhl-Fehlert

Drommer

Rosenbruch

. Effects of ciprofloxacin on joint cartilage in immature dogs immediately after dosing and after a 5-month treatment-free period. Arch Toxicol. 2004;78:418-424.

Burkhart

Walterspiel

Schaad

. Quinolone arthropathy in animals versus children. Clin Infect Dis. 1997;25:1196-1204.

Vorman

Forster

Zippel

. Effects of magnesium deficiency on magnesium and calcium content in bone and cartilage in developing rats in correlation to chondrotoxicity. Calcif Tissue Int. 1997;61:230-238.

10.

Williams

Attia

Wickiewicz

Hannafin

. The effect of ciprofloxacin on tendon, paratenon, and capsular fibroblast metabolism. Am J Sports Med. 2000;28:364-369.

11.

Saez-Llorens

McCoig

Feris

. Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin. Pediatr Infect Dis J. 2002;21:14-21.

12.

Pichichero

Arguedas

Dagan

. Safety and efficacy of gatifloxacin therapy for children with recurrent acute otitis media (AOM) and/or AOM treatment failure. Clin Infect Dis. 2005;41:470-478.

13.

US Food and Drug Administration. Drug approval package [ciprofloxacin]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019537s073,020780s030lbl.pdf. Accessed on April 15, 2015.

14.

Bradley

Jackson

. The use of systemic and topical fluoroquinolones. Am Acad Pediatr. 2011;128:e1034-e1045.

15.

Noel

Bradley

Kauffman

. Comparative safety profile of levofloxacin in 2523 children with a focus of four musculoskeletal disorders. Pediatr Infect Dis J. 2007;26:879-891.

16.

Bradley

Kauffman

Balis

. Assessment of musculoskeletal toxicity 5 years after therapy with levofloxacin. Am Acad Pediatr. 2014;134:e146-153.

17.

Taketomo

Hodding

Kraus

. Pediatric and Neonatal Dosage Handbook. 21st ed. Hudson, OH: Lexi-Comp, Inc; 2015.